80
Participants
Start Date
February 29, 2004
Primary Completion Date
December 31, 2006
Study Completion Date
December 31, 2006
SGN-30 (anti-CD30 mAb)
Cornell University, New York
Roswell Park Cancer Institute, Buffalo
University of Rochester, Rochester
Georgetown University, Washington D.C.
University of Maryland Greenebaum Cancer Center, Baltimore
Duke University Medical Center, Durham
University of Miami, Miami
University of Minnesota, Minneapolis
Northwestern University, Chicago
Washington University School of Medicine, St Louis
University of Texas MD Anderson Cancer Center, Houston
University of Califorinia at Los Angeles, Los Angeles
Kaiser Permanente, Portland
Oregon Health Science University, Portland
University of Washington, Seattle
University of Alabama, Birmingham, Birmingham
Dana Farber Cancer Institute, Boston
University of Nebraska, Omaha
Seagen Inc.
INDUSTRY